Your session is about to expire
← Back to Search
Tyrosine Kinase Inhibitor
Cabozantinib + Pemetrexed for Non-Small Cell Lung Cancer
Phase 1
Waitlist Available
Led By Nagla A Karim, MD, PhD
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years or older.
Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up os measured through study completion, and an average of 1 year
Awards & highlights
Study Summary
This trial will explore whether combining cabozantinib with pemetrexed can effectively treat patients with advanced non-small cell lung cancer, urothelial cancer, or malignant mesothelioma.
Eligible Conditions
- Non-Small Cell Lung Cancer
- Bladder Cancer
- Mesothelioma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ to be measured through study completion; an average of 1 year.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~to be measured through study completion; an average of 1 year.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed
Secondary outcome measures
Heart rate
Overall survival (OS).
Progression-free survival (PFS)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Cabozantinib + PemetrexedExperimental Treatment2 Interventions
Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
2020
Completed Phase 2
~1080
Pemetrexed
2014
Completed Phase 3
~5250
Find a Location
Who is running the clinical trial?
Augusta UniversityLead Sponsor
210 Previous Clinical Trials
85,047 Total Patients Enrolled
Nagla A Karim, MD, PhDPrincipal InvestigatorAugusta University Georgia Cancer Center
1 Previous Clinical Trials
10 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger